Pharmacokinetics and safety of a raltegravir-containing regimen in children aged 4 weeks to 2 years living with human immunodeficiency virus and receiving rifampin for tuberculosis
Written By
Krogstad P, Samson P, Acosta EP, Moye J, Townley E, Bradford S, Brown E, Denson K, Graham B, Hovind L, Sise T, Teppler H, Mathiba SR;, Fairlie L, Winckler JL, Slade G, Meyers T, International Maternal Pediatric Adolescent AIDS Clinical Trials Network P1101 Team
